Study on the Protective Effect of Edaravone on Myocardial Ischemia Reperfusion Injury
Abstract
Objective: Discussion the role of edaravone as a free radical scavenger in protective effect of thrombolysis in acute myocardial ischemia reperfusion injury. Besides compared with the control group and analyze the possible mechanism which is widely used in clinical setting. Method: 80 patients hospitalized within year 2012−2013 with acute myocardial infarction (AMI) were treated with intravenous thrombolytic therapy, and were divided into treatment group (n = 41) and control group (n = 39). Edaravone injection 30 mg + 0.9% normal saline solution 100 mL with intravenous drip, BID for 14 days was given to the treatment group before and after thrombolytic treatment. Whereas, control group was treated with intravenous drip of placebo. Both groups were monitored by echocardiography and hemodynamic monitoring, and the myocardium was measured by echocardiography. Coronary artery CT was used to determine the degree of obstruction. Results: Compared with the control group, pain and reperfusion arrhythmia in treatment group was reduced. The area of myocardial wall movement disorder was significantly decreased (p < 0.05), the difference was statistically significant. CT result comparing treatment group and control group and show that rate of coronary recanalization increases 1.7 times (p < 0.01), the differences were statistically significant. Conclusion: For acute myocardial ischemia injection of edaravone before reperfusion and combine with pharmacological treatment can alleviate myocardial ischemia reperfusion injury, effectively scavenge oxygen free radicals and improve the ability of antioxidant. Both improve the thrombolytic treatment and protective effect for acute myocardial ischemia were significant. Hence, edaravone can is a kind of new milestone in the clinical cardiovascular drugs.
References
2. Gottlieb RA. Cell death pathways in acute ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther. 2011;16(4):233‒238.
3. Zhao SP. Guidelines for diagnosis and treatment of cardiovascular disease to interpret. Beijing: People’s Medical Publishing House;2008:10.
4. Jennings RB, Sommers HM, Smyth GA, et al. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960;6(70):68‒78.
5. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. 1985;76(5):1713‒1719.
6. Xia Q, Qian LB. Cardiac and cerebral ischemia/reperfusion injury and prevention strategies. Journal of Zhejiang University (Medical Science). 2010;39(6):551‒558.
7. Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J. 2000;139(2):115‒119.
8. Shrader D. On dying more than one death. Hastings Cent Rep. 1986;16(1):12‒17.
9. Shen AC, Jennings RB. Kinetics of calcium accumulation in acute myocardial ischemic injury. Am J Pathol. 1972;67(3):441‒447.
10. Hoole SP, Heck PM, Sharples L, et al. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation. 2009;119(6):820‒827.
11. Fang F, Li D, Pan H, et al. Luteolin inhibits apoptosis and improves cardiomyocyte contractile function through the PI3K/Akt pathway in simulated ischemia/reperfusion. Pharmacology. 2011;88(3‒4):149‒158.
12. Zhu J, Rebecchi MJ, Glass PS, et al. Cardioprotection of the aged rat heart by GSK-3beta inhibitor is attenuated: age-related changes in mitochondrial permeability transition pore modulation. Am J Physiol Heart Circ Physiol. 2011;300(3):922‒930.
13. Mao HD, Song HF, Mo WQ, et al. Edaravone in treatment of acute myocardial infarction reperfusion injury of curative effect observation. Contemporary Chinese Medicine. 2011;18(2):48‒50.
14. Liu ZJ, Li YQ, et al. Edaravone on reperfusion injury of myocardial infarction treated with intravenous thrombolytic therapy. Chinese and Western Modern Medicine. 2009;18(8):889‒890.
Copyright (c) 2013 Hui Hou
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
